Rare & Genetic Diseases
| 3 min read
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
| 5 min read
A new study finds that non-core and non-essential procedures may add significant burden to participants and research sites.
| 4 min read
Greater focus on non-animal testing methods in the UK, a new CRISPR treatment to lower cholesterol, and positive results for a BTK inhibitor in MS led the news this week.
| 4 min read
Radiprodil is in development as the first therapy designed to directly address the underlying biology of GRIN-related neurodevelopmental disorder.
| 6 min read
With the first wave of FDA-approved siRNA drugs under their belt, companies are racing to expand into new tissues and indications.
| 5 min read
After a decade of promise, AAV therapies are now confronting economic, clinical, and regulatory hurdles.
| 3 min read
People with erythropoietic protoporphyria (EPP) must go to great lengths to avoid sun exposure. There have been no approved treatments that address the disease mechanism, but a new drug could change that.
| 4 min read
The HDAC inhibitor givinostat has received regulatory approval in the US, EU, and UK for patients six years and older.
| 3 min read
Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.
| 4 min read
A gene therapy trial halted after a child’s death, a CRISPR test to detect tuberculosis, a new device for antisense therapies, and more led the news this week.
| 4 min read
AI is making studies more patient-centric, data-driven, and adaptable, ensuring patients can find, join, and stay in the trials that matter most.
| 4 min read
New results from an anti-seizure medication and blood cancer drug, a new AI platform, and a novel heart disease drug led drug discovery this week.
